Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Literature DB >> 27738953

The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Abstract

Current marketed dry powder inhalers utilize the energy from patient inspiration to fluidize and disperse bulk powder agglomerates into respirable particles. Variations in patient inspiratory flow profiles can lead to marked differences in total lung dose (TLD), and ultimately patient outcomes for an inhaled therapeutic. The present review aims to quantitate the flow rate dependence in TLD observed for a number of drug/device combinations using a new metric termed the Q index. With this data in hand, the review explores key attributes in the design of the formulation and device that impact flow rate dependence. The review also proposes alternative in vitro methods to assess flow rate dependence that more closely align with in vivo observations. Finally, the impact of variations in flow rate on lung function for inhaled bronchodilators is summarized.

Entities: Species

Keywords: Bronchodilator; Inertial impaction parameter; Inhalation; Total Lung Dose (TLD)

Mesh：

Substances：

Year: 2016 PMID： 27738953 DOI： 10.1007/s11095-016-2050-x

Source DB: PubMed Journal: Pharm Res ISSN： 0724-8741 Impact factor: 4.200

77 in total

1. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver.

Authors: Jeffry Weers; Keith Ung; John Le; Nagaraja Rao; Brian Ament; George Axford; David Maltz; Leo Chan
Journal: J Aerosol Med Pulm Drug Deliv Date: 2012-06-12 Impact factor: 2.849

2. Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. extension of archival calibration to 15 L/min.

Authors: Virgil A Marple; Bernard A Olson; Kumaragovindhan Santhanakrishnan; Daryl L Roberts; Jolyon P Mitchell; Buffy L Hudson-Curtis
Journal: J Aerosol Med Date: 2004

Review 3. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations.

Authors: Matthew D Jones; Robert Price
Journal: Pharm Res Date: 2006-08 Impact factor: 4.200

4. Lung deposition of budesonide from turbuhaler in asthmatic children.

Authors: J H Wildhaber; S G Devadason; J M Wilson; C Roller; T Lagana; L Borgström; P N LeSouëf
Journal: Eur J Pediatr Date: 1998-12 Impact factor: 3.183

5. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction.

Authors: P Zanen; L T Go; J W Lammers
Journal: Thorax Date: 1996-10 Impact factor: 9.139

Review 6. The PulmoSphere™ platform for pulmonary drug delivery.

Authors: Jeffry Weers; Thomas Tarara
Journal: Ther Deliv Date: 2014-03

7. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older.

Authors: H A Tiddens; D E Geller; P Challoner; R J Speirs; K C Kesser; S E Overbeek; D Humble; S B Shrewsbury; T A Standaert
Journal: J Aerosol Med Date: 2006

8. Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma.

Authors: Israel Amirav; Michael T Newhouse; Yasser Mansour
Journal: Pediatr Pulmonol Date: 2005-05

9. Inhalation of tobramycin using simulated cystic fibrosis patient profiles.

Authors: Alfred Haynes; David Geller; Jeffry Weers; Brian Ament; Richard Pavkov; Richard Malcolmson; Laurie Debonnett; Paul Mastoridis; Anthony Yadao; Silvia Heuerding
Journal: Pediatr Pulmonol Date: 2016-05-01

10. Inhaled mannitol improves lung function in cystic fibrosis.

Authors: Anna Jaques; Evangelia Daviskas; James A Turton; Karen McKay; Peter Cooper; Robert G Stirling; Colin F Robertson; Peter T P Bye; Peter N LeSouëf; Bruce Shadbolt; Sandra D Anderson; Brett Charlton
Journal: Chest Date: 2008-03-13 Impact factor: 9.410

9 in total

1. In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.

Authors: Rain Jõgi; Satu Lähelmä; Mikko Vahteristo; Anita Happonen; Jussi Haikarainen
Journal: J Aerosol Med Pulm Drug Deliv Date: 2018-10-09 Impact factor: 2.849

Review 2. The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates.

Authors: Andrew R Clark; Jeffry G Weers; Rajiv Dhand
Journal: J Aerosol Med Pulm Drug Deliv Date: 2019-10-31 Impact factor: 2.849

Review 3. Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes.

Authors: Mark L Levy; Will Carroll; José L Izquierdo Alonso; Claus Keller; Federico Lavorini; Lauri Lehtimäki
Journal: Adv Ther Date: 2019-09-02 Impact factor: 3.845

Review 4. Comparison of Phospholipid-Based Particles for Sustained Release of Ciprofloxacin Following Pulmonary Administration to Bronchiectasis Patients.

Authors: Jeffry Weers
Journal: Pulm Ther Date: 2019-11-15

Review 5. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape.

Authors: Federico Lavorini; Christer Janson; Fulvio Braido; Georgios Stratelis; Anders Løkke
Journal: Ther Adv Respir Dis Date: 2019 Jan-Dec Impact factor: 4.031

6. The contribution of patients' lung function to the inspiratory airflow rate achievable through a DPIs' simulator reproducing different intrinsic resistance rates.

Authors: Roberto W Dal Negro; Paola Turco; Massimiliano Povero
Journal: Multidiscip Respir Med Date: 2021-04-15